Conexeu Sciences Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Apr '26 Apr 30, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023
Selling, General & Admin	6.86	3.66	0.41	0.04
Research & Development	0.34	0.27	0.24	-
Operating Expenses	7.23	3.95	0.64	0.04
Operating Income	-7.23	-3.95	-0.64	-0.04
Interest Expense	-	-0	-0.02	-
Interest & Investment Income	0.1	0	-	-
Currency Exchange Gain (Loss)	-0.02	-0	0.01	0
Other Non Operating Income (Expenses)	-0.04	-0.01	-0	-
EBT Excluding Unusual Items	-7.2	-3.97	-0.66	-0.04
Other Unusual Items	-	0.04	0.18	-
Pretax Income	-7.2	-3.92	-0.47	-0.04
Net Income	-7.2	-3.92	-0.47	-0.04
Net Income to Common	-7.2	-3.92	-0.47	-0.04
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	18	13	7	2
Shares Outstanding (Diluted)	18	13	7	2
Shares Change	-	87.74%	286.25%	-
EPS (Basic)	-0.39	-0.31	-0.07	-0.02
EPS (Diluted)	-0.39	-0.31	-0.07	-0.02
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Apr '26 Apr 30, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023
Free Cash Flow	-4.38	-1.69	-0.23	-0
Free Cash Flow Per Share	-0.24	-0.13	-0.03	-0.00
EBITDA	-7.2	-3.93	-	-
D&A For EBITDA	0.03	0.02	-	-
EBIT	-7.23	-3.95	-0.64	-0.04
Advertising Expenses	-	0.05	0.01	-

SEC Filings: 10-K · 10-Q